EUCTR2005-002423-13-IT进行中（未招募）不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 630
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Completion of 24 weeks of treatment with tocilizumab (MRA) in WA17822, and scheduled to receive the first tocilizumab (MRA) infusion in WA18695 between 4 and 12 weeks after the last iv infusion in WA17822. Patients that are prevented from enrollment prior to 12 weeks after the last iv infusion in WA17822 due to administrative delays outside of the control of the investigator and upon discussion with Roche may be included if they meet all other inclusion criteria, but will undergo a separate analysis of the study results. 2) Able and willing to give written informed consent and comply with the requirements of the study protocol. 3) Have received methotrexate at a stable dose of between 10 and 25 mg/week (p.o. or parenteral) since the last administration of study drug in WA17822. 4) Oral corticosteroids (≤10 mg/day prednisone or equivalent) and NSAIDS (up to the maximum recommended dose) are permitted if dose stable since the last administration of study drug in WA17822. 5) Must be willing to receive oral folate (at least 5 mg/week). 6) Females of child-bearing potential and males with female partners of childbearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or IUD). 7) If female and of child-bearing potential, the patient must have a negative urine pregnancy test at baseline.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Treatment with any investigational agent since the last administration of study drug in WA17822. 2) Previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20) 3) Treatment with iv gamma globulin, plasmapheresis or Prosorba column since the last administration of study drug in WA17822. 4) Treatment with an anti-TNF or anti-IL1 agent, or a T-cell costimulation modulator since the last administration of study drug in WA17822. 5) Parenteral, intramuscular or intra-articular corticosteroids within 6 weeks prior to baseline in WA18695. 6) Immunization with a live/attenuated vaccine since the last administration of study drug in WA17822. 7) Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation. 8) History of severe allergic or anaphylactic reaction to human, humanized or murine monoclonal antibodies. 9) Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (incl. obstructive pulmonary disease), renal, hepatic, endocrine (incl. uncontrolled diabetes mellitus), immunologic or gastrointestinal disease; history of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower GI disease such as Crohn s disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations for whom a favourable benefit/risk assessment for study continuation cannot be documented. 10) Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, clinically significant abnormalities on chest X-ray as determined by the investigator, HIV, hepatitis B and C, and Herpes zoster, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with iv antibiotics within four weeks prior to baseline or oral antibiotics within two weeks prior to baseline. 11) Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematological malignancies and solid tumors, except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years. 12) Patients whose AST or ALT ≥ 3 times ULN, bilirubin > 2 times ULN or > 2.5 mg/dL (43 umol/L), neutrophils < 1000/mm3 (1 x 103 /uL or 1 GI/L), or who have an infection.
研究者
相似试验
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2005-002909-23-ITF. Hoffmann - La Roche Ltd2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-DEF Hoffmann-La Roche AG2,420
进行中（未招募）
1 期
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. - NARheumatoid arthritisEUCTR2005-002909-23-GBF Hoffmann La-Roche AG2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-NOF Hoffmann La-Roche AG2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. - NARheumatoid arthritisEUCTR2005-002909-23-PTF Hoffmann La-Roche AG2,420